Search results
Found 6 matches for
Minas Salib, in the group led by Tim Viney and Peter Somogyi, has discovered a new type of neuronal pathway that may be important in memory. For the encoding and recall of episodic memories, nerve cells in the cerebral cortex are activated in precisely timed sequences. Rhythmicity facilitates the coordination of neuronal activity and these rhythms are detected as oscillations of different frequencies, such as 5–12 Hz theta oscillations. Degradation of these rhythms, such as through neurodegeneration, causes memory deficits. The medial septum, a part of the basal forebrain that innervates the hippocampal formation, contains neurons that fire with a high degree of rhythmicity (HRNs) and others that fire with a low degree of rhythmicity (LRNs). These distinct types of neuron may contribute differentially to the coordination of cortical neuronal activity. Minas and colleagues discovered that GABAergic LRNs preferentially innervate the dentate gyrus and the CA3 area of the hippocampus, regions important for episodic memory. These neurons act in parallel with the HRNs mostly via transient inhibition of inhibitory neurons. A figure from the paper describing these results was chosen to illustrate the front cover of the 5 June issue of Journal of Neuroscience.
Professor Angela Russell receives 2021 Harrington UK Rare Disease Scholar Award
Department Russell Group
15 October 2020
Angela Russell, Professor of Medicinal Chemistry in the Oxford Departments of Pharmacology and Chemistry, has been announced as one of the five recipients of the inaugural UK Rare Disease Scholar Award, presented by the Harrington Discovery Institute (HDI).
Russell group research reveals molecular target of the Utrophin modulator Ezutromid
Department Russell Group
6 January 2020
A collaboration between the Russell group (Chemistry and Pharmacology) and the Davies group (Physiology, Anatomy and Genetics) has identified, via a chemical proteomics and phenotypic profiling strategy, the arylhydrocarbon receptor (AhR) as the molecular target of ezutromid, the utrophin modulator that recently completed a Phase 2 clinical trial in Duchenne muscular dystrophy patients.
Nature Comms paper highlights a new strategy for targeting protein-protein interactions (PPIs) for the development of new small molecule therapeutics
Department Russell Group
25 September 2018